Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MK-8189 in Schizophrenia and Healthy Participants
NCT03565068Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elpipodect in schizophrenia (8 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced One or More Adverse Events and Number of Participants Who Discontinued Study Treatment Due to an AE. Started Jun 2018; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03565068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565068.